Antoine Pariente

Dr. Antoine Pariente did is MD in Pharmacology and Public Health and completed his training with a PhD In Pharmacoepidemiology focussing on population Impact of drugs in dementia. From 2016 to 2021 he headed the Bordeaux Pharmacovigilance Centre; from 2018 to 2021, he was additionally appointed as a scientific independent expert towards the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) where he was selected to chair the Interest Group for Impact of Pharmacovigilance regulatory Actions Assessment. During the 2015-2019 period, he coordinated the French national academic platform for pharmacoepidemiology DRUGS-SAFE (Drugs Systematized Assessment in real-liFe environment). After being selected through a national call emitted by the French Drug Agency, this was transformed into the DRUGS-SAFER Center. Antoine Pariente also coordinates this academic center which has been appointed by the authorities to provide real-world evidence supporting decision-making regarding the use and safety of drugs. He chaired from 2016 to 2020 the Bordeaux Population health research team “Pharmacoepidemioloy – Drugs and Population Health”. He is now the director of the BPH AHeaD team created from the merging of the Pharmaco, ERIAS (headed by Gayo Diallo), and IETO (headed by Emmanuel Lagarde) teams.